JP7723030B2 - チアゾロ［５，４－ｂ］ピリジンＭＡＬＴ－１阻害剤 - Google Patents

チアゾロ［５，４－ｂ］ピリジンＭＡＬＴ－１阻害剤

Info

Publication number
JP7723030B2
JP7723030B2 JP2023052720A JP2023052720A JP7723030B2 JP 7723030 B2 JP7723030 B2 JP 7723030B2 JP 2023052720 A JP2023052720 A JP 2023052720A JP 2023052720 A JP2023052720 A JP 2023052720A JP 7723030 B2 JP7723030 B2 JP 7723030B2
Authority
JP
Japan
Prior art keywords
methyl
mmol
pyridin
methoxyethyl
thiazolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023052720A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023152927A5 (https=
JP2023152927A (ja
Inventor
プニート・クマール
アンソニー・マストラッチオ
マーク・ミルズ
アンドルー・ウィリアム・フィリップス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of JP2023152927A publication Critical patent/JP2023152927A/ja
Publication of JP2023152927A5 publication Critical patent/JP2023152927A5/ja
Priority to JP2025128083A priority Critical patent/JP2025156455A/ja
Application granted granted Critical
Publication of JP7723030B2 publication Critical patent/JP7723030B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023052720A 2022-03-31 2023-03-29 チアゾロ［５，４－ｂ］ピリジンＭＡＬＴ－１阻害剤 Active JP7723030B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025128083A JP2025156455A (ja) 2022-03-31 2025-07-31 チアゾロ［５，４－ｂ］ピリジンＭＡＬＴ－１阻害剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263362302P 2022-03-31 2022-03-31
US63/362,302 2022-03-31

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025128083A Division JP2025156455A (ja) 2022-03-31 2025-07-31 チアゾロ［５，４－ｂ］ピリジンＭＡＬＴ－１阻害剤

Publications (3)

Publication Number Publication Date
JP2023152927A JP2023152927A (ja) 2023-10-17
JP2023152927A5 JP2023152927A5 (https=) 2024-12-23
JP7723030B2 true JP7723030B2 (ja) 2025-08-13

Family

ID=86185307

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023052720A Active JP7723030B2 (ja) 2022-03-31 2023-03-29 チアゾロ［５，４－ｂ］ピリジンＭＡＬＴ－１阻害剤
JP2025128083A Pending JP2025156455A (ja) 2022-03-31 2025-07-31 チアゾロ［５，４－ｂ］ピリジンＭＡＬＴ－１阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025128083A Pending JP2025156455A (ja) 2022-03-31 2025-07-31 チアゾロ［５，４－ｂ］ピリジンＭＡＬＴ－１阻害剤

Country Status (13)

Country Link
US (2) US11993613B2 (https=)
EP (2) EP4729059A2 (https=)
JP (2) JP7723030B2 (https=)
KR (1) KR20240168420A (https=)
CN (1) CN119855821A (https=)
AR (2) AR128917A1 (https=)
AU (1) AU2023243460A1 (https=)
CA (1) CA3246085A1 (https=)
CO (1) CO2024014618A2 (https=)
IL (1) IL316288A (https=)
MX (1) MX2024012018A (https=)
TW (1) TW202345806A (https=)
WO (1) WO2023192913A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202345806A (zh) 2022-03-31 2023-12-01 美商艾伯維有限公司 噻唑并〔５，４－ｂ〕吡啶ｍａｌｔ－１抑制劑
WO2025223516A1 (zh) * 2024-04-24 2025-10-30 首药控股(北京)股份有限公司 一种抑制剂杂环化合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018226150A1 (en) 2017-06-05 2018-12-13 Medivir Aktiebolag Pyrazolopyrimidine as malt-1 inhibitors
JP2019522035A (ja) 2016-07-29 2019-08-08 ルピン・リミテッド Ｍａｌｔ１阻害剤としての置換チアゾロ−ピリジン化合物

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2496666A1 (fr) 1980-12-22 1982-06-25 Ici Pharma Nouveaux derives de cephalosporine et composition pharmaceutique les contenant
US5851741A (en) 1986-01-24 1998-12-22 Fuji Photo Film Co., Ltd. Method for the formation of color images
US5658889A (en) 1989-01-24 1997-08-19 Gensia Pharmaceuticals, Inc. Method and compounds for aica riboside delivery and for lowering blood glucose
US5726302A (en) 1989-09-15 1998-03-10 Gensia Inc. Water soluble adenosine kinase inhibitors
US5795977A (en) 1989-09-15 1998-08-18 Metabasis Therapeutics, Inc. Water soluble adenosine kinase inhibitors
US5646128A (en) 1989-09-15 1997-07-08 Gensia, Inc. Methods for treating adenosine kinase related conditions
US6251911B1 (en) 1996-10-02 2001-06-26 Novartis Ag Pyrimidine derivatives and processes for the preparation thereof
DE10028575A1 (de) 2000-06-14 2002-03-14 Basf Ag Integrinliganden
AU4890301A (en) 2000-04-17 2001-10-30 Dong Wha Pharmaceutical Industrial Co., Ltd. 6-methylnicotinamide derivatives as antiviral agents
EP1314733A1 (en) 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
US20040185429A1 (en) 2002-12-09 2004-09-23 Judith Kelleher-Andersson Method for discovering neurogenic agents
SE0400284D0 (sv) 2004-02-10 2004-02-10 Astrazeneca Ab Novel compounds
GB0423554D0 (en) 2004-10-22 2004-11-24 Cancer Rec Tech Ltd Therapeutic compounds
JP2006241089A (ja) 2005-03-04 2006-09-14 Astellas Pharma Inc ピロロピリミジン誘導体またはその塩
WO2007058482A1 (en) 2005-11-16 2007-05-24 Lg Life Sciences, Ltd. Novel inhibitors of protein kinase
TW200808325A (en) 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
WO2008073929A1 (en) 2006-12-11 2008-06-19 Wyeth Ion channel modulators
JP2010514693A (ja) 2006-12-22 2010-05-06 ノバルティス アーゲー Ｐｄｋ１阻害のためのキナゾリン
JP5219583B2 (ja) 2008-03-31 2013-06-26 住友化学株式会社 組成物、光学フィルムとその製造方法、光学部材及び表示装置
JP5219594B2 (ja) 2008-04-08 2013-06-26 住友化学株式会社 組成物、光学フィルム及びフラットパネル表示装置
US20100121052A1 (en) 2008-06-20 2010-05-13 Rama Jain Novel compounds for treating proliferative diseases
UY31984A (es) 2008-07-16 2010-02-26 Boehringer Ingelheim Int DERIVADOS DE 1-(3,4-difluorobencil)-6-oxo-1,6-dihidropirimidin-5-carboxamidas N-sustituidas y de 2-(3,4-difluorobencil)-3-oxo-2,3-dihidro-1H-pirazol-4-carboxamidas N-sustituidas.
JP5443720B2 (ja) 2008-09-05 2014-03-19 住友化学株式会社 組成物、光学フィルム及びその製造方法、光学部材ならびに表示装置
SI2396307T1 (sl) 2009-02-11 2015-02-27 Merck Patent Gmbh Novi amino azaheterockliäśni karboksamidi
UY32470A (es) 2009-03-05 2010-10-29 Boehringer Ingelheim Int Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
WO2010147898A2 (en) 2009-06-15 2010-12-23 Rigel Pharmaceuticals, Inc. Small molecule inhibitors of spleen tyrosine kinase (syk)
US8822700B2 (en) 2009-09-11 2014-09-02 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8759332B2 (en) 2009-09-11 2014-06-24 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8703938B2 (en) 2009-09-11 2014-04-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8815928B2 (en) 2009-09-11 2014-08-26 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8927709B2 (en) 2009-09-11 2015-01-06 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US9556426B2 (en) 2009-09-16 2017-01-31 Celgene Avilomics Research, Inc. Protein kinase conjugates and inhibitors
US8586604B2 (en) 2010-08-20 2013-11-19 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin E2 synthase-1
US8759537B2 (en) 2010-08-20 2014-06-24 Boehringer Ingelheim International Gmbh 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
RU2632900C2 (ru) 2010-11-19 2017-10-11 Лиганд Фармасьютикалс Инкорпорейтед Гетероциклические амины и их применение
WO2012075232A1 (en) 2010-12-04 2012-06-07 Trevena, Inc. Opioid receptor ligands and methods of using and making the same
UY33779A (es) 2010-12-10 2012-07-31 Boehringer Ingelheim Int ?2-(fenilamino)-1H-bencimidazol-5-carboxamidas novedosas?
US8466186B2 (en) 2010-12-10 2013-06-18 Boehringer Ingelheim International Gmbh Compounds
WO2013038308A1 (en) 2011-09-15 2013-03-21 Glenmark Pharmaceuticals S.A. SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS AS mPGES-1 INHIBITORS
HRP20180037T1 (hr) 2012-04-17 2018-03-23 Fujifilm Corporation Heterociklični spoj koji sadrži dušik ili njegovu sol
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
CA2895426A1 (en) 2012-12-20 2014-06-26 Bayer Pharma Aktiengesellschaft Bet-protein-inhibiting dihydroquinoxalinones
WO2014146246A1 (en) 2013-03-19 2014-09-25 Merck Sharp & Dohme Corp. Cycloalkyl nitrile pyrazolo pyridones as janus kinase inhibitors
EP3195866B1 (en) 2014-08-22 2020-11-18 FUJIFILM Corporation Pharmaceutical composition for treating flt3 mutation-positive cancer, mutant flt3 inhibitor and uses thereof
WO2016172631A2 (en) 2015-04-24 2016-10-27 President And Fellows Of Harvard College Substrate selective inhibitors of insulin-degrading enzyme (ide) and uses thereof
EP3307726B1 (en) 2015-06-11 2020-05-20 International Society for Drug Development S.r.l. 2-oxo-1,2-dihydropyridine-3-carboxamide compounds and their use as inhibitors of pdk1
EP3350158A4 (en) 2015-09-16 2019-05-08 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
US20180273573A1 (en) 2015-10-01 2018-09-27 Memorial Sloan-Kettering Cancer Center Inhibitors of menaquinone biosynthesis
SI3371171T1 (sl) 2015-11-02 2024-03-29 Blueprint Medicines Corporation Inhibitorji ret
GB201603311D0 (en) 2016-02-25 2016-04-13 Jakobsson Per Johan New uses and methods
WO2017201585A1 (en) 2016-05-26 2017-11-30 Genea Ip Holdings Pty Ltd Modulators of dux4 for regulation of muscle function
US11135207B2 (en) 2016-12-13 2021-10-05 Centaurus Therapeutics Inhibitors of dihydroceramide desaturase for treating disease
CA3047404A1 (en) 2016-12-23 2018-06-28 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use
GB201707938D0 (en) 2017-05-17 2017-06-28 Univ Sheffield Compounds
AU2018286247B2 (en) 2017-06-14 2021-12-23 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Syk inhibitor and use method therefor
CN110709402B (zh) 2017-06-15 2022-05-10 浙江海正药业股份有限公司 杂芳基并嘧啶酮类衍生物、其制备方法及其在医药上用途
EP3707138B1 (en) 2017-11-06 2022-07-13 Bristol-Myers Squibb Company Isofuranone compounds useful as hpk1 inhibitors
US10844044B2 (en) 2018-06-14 2020-11-24 Vanderbilt University WDR5 inhibitors and modulators
WO2020031107A1 (en) 2018-08-08 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
US12187686B2 (en) 2018-09-07 2025-01-07 H. Lee Moffitt Cancer Center And Research Institute, Inc. BRD4-JAK2 inhibitors
EP3898630B1 (en) 2018-12-17 2023-05-10 F. Hoffmann-La Roche AG Novel imidazopyrazine derivatives
CN112409331B (zh) 2019-08-21 2024-02-20 上海翰森生物医药科技有限公司 杂环类衍生物抑制剂、其制备方法和应用
CA3157026A1 (en) 2019-10-07 2021-04-15 D.E. Shaw Research, Llc Arylmethylene aromatic compounds as kv1.3 potassium shaker channel blockers
GB201914910D0 (en) 2019-10-15 2019-11-27 Sentinel Oncology Ltd Pharmaceutical compounds
IL296025A (en) 2020-03-02 2022-10-01 Sironax Ltd Proptosis inhibitors - diarylamine para-acetamides
CN113527291B (zh) 2020-04-13 2025-07-22 广东东阳光药业股份有限公司 Ret抑制剂、其药物组合物及其用途
CA3191279A1 (en) 2020-08-28 2022-03-03 Yi Liu Heterocyclic compounds and uses thereof
CN116437913A (zh) 2020-09-23 2023-07-14 艾其林医药公司 用于治疗补体介导的病症的药物化合物
JP7818011B2 (ja) 2020-10-16 2026-02-19 レラファイド バイオサイエンシーズ， インコーポレイテッド Ｍａｌｔ１モジュレーターおよびその使用
WO2022081995A1 (en) 2020-10-16 2022-04-21 Rheos Medicines, Inc. Malt1 modulators and uses thereof
IL302440A (en) 2020-10-30 2023-06-01 Calico Life Sciences Llc Combined pressure pathway modulators
GB202018412D0 (en) 2020-11-23 2021-01-06 Exscientia Ltd Malt-1 modulators ii
TW202345806A (zh) 2022-03-31 2023-12-01 美商艾伯維有限公司 噻唑并〔５，４－ｂ〕吡啶ｍａｌｔ－１抑制劑

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019522035A (ja) 2016-07-29 2019-08-08 ルピン・リミテッド Ｍａｌｔ１阻害剤としての置換チアゾロ−ピリジン化合物
WO2018226150A1 (en) 2017-06-05 2018-12-13 Medivir Aktiebolag Pyrazolopyrimidine as malt-1 inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Expert Opinion on Therapeutic Patents，2021年，Vol.31，pp.1079-1096

Also Published As

Publication number Publication date
CA3246085A1 (en) 2023-10-05
AR128917A1 (es) 2024-06-26
EP4729059A2 (en) 2026-04-22
US20230312601A1 (en) 2023-10-05
MX2024012018A (es) 2024-11-08
AU2023243460A1 (en) 2024-10-24
CO2024014618A2 (es) 2024-11-08
CN119855821A (zh) 2025-04-18
WO2023192913A1 (en) 2023-10-05
US20250084099A1 (en) 2025-03-13
EP4499650A1 (en) 2025-02-05
JP2025156455A (ja) 2025-10-14
KR20240168420A (ko) 2024-11-29
IL316288A (en) 2024-12-01
AR134155A2 (es) 2025-12-10
JP2023152927A (ja) 2023-10-17
TW202345806A (zh) 2023-12-01
US11993613B2 (en) 2024-05-28

Similar Documents

Publication Publication Date Title
AU2020343681B2 (en) Heterocyclic RIP1 kinase inhibitors
AU2020341708B2 (en) RIP1 inhibitory compounds and methods for making and using the same
KR102824962B1 (ko) 헤테로시클릭 rip1 억제 화합물
JP2025156455A (ja) チアゾロ［５，４－ｂ］ピリジンＭＡＬＴ－１阻害剤
AU2021300831B2 (en) RIP1k inhibitors
CN115403581B (zh) 作为irak4抑制剂的杂环化合物
CA3149900C (en) Rip1 inhibitory compounds and methods for making and using the same
HK40082783A (en) Rip1 inhibitory compounds and methods for making and using the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241225

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250701

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250731

R150 Certificate of patent or registration of utility model

Ref document number: 7723030

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150